49
CD52_Autoimmune diseases
Walter and Eliza Hall
Peptide
Immunology
Pre-Clinical
CD52 is a small GPI-anchored glycopeptide expressed on leukocytes, and up-regulated and shed by activated T cells. CD52 suppresses T cell function by binding the Siglec-10 receptor and also suppresses the innate immune response. Administration of soluble hCD52-Fc reduces incidence of diabetes and sepsis in pre-clinical models, with no demonstrable adverse effects. Ongoing studies characterizing key co-factors, CD52 glycosylation structure-function may yield new IP.
PCT/AU2012/001411
PCT/AU2013/000292